Mechanism of action and resistance to monoclonal antibody therapy.
about
Complement in monoclonal antibody therapy of cancerThe therapeutic use of rituximab in non-Hodgkin's lymphoma.Effect of alemtuzumab on intestinal intraepithelial lymphocytes and intestinal barrier function in cynomolgus modelDepleting T-cell subpopulations in organ transplantation.Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation.Hairy cell leukemia-new genes, new targets.Lipid-based delivery of CpG oligodeoxynucleotides for cancer immunotherapy.RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF-κB/Snail/YY1/RKIP resistance-driver loopApplication of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells.Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia.Low pH impairs complement-dependent cytotoxicity against IgG-coated target cells.Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol.Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: sCD40L-caspase 3 chimeric protein for treating B-cell malignancies.How I treat patients with relapsed chronic lymphocytic leukaemia.
P2860
Q26860800-0B15B805-7C20-4B87-B01C-7718EF0B2CDBQ36700912-8F8C0B11-38A7-4874-8AA2-71961E38CCB6Q36807186-BE3E15E8-766E-43F3-A13B-1A7D6F7A2C33Q37316082-2D4E7FAE-015C-4704-A9A7-B3EA5D29058BQ38009874-30693494-CB9E-438B-8AD6-92DF07CEDC7AQ38124726-4D6DDA10-55A6-4C18-AC04-2D6C2DEBC180Q38177364-AC22C489-ED3C-4E86-B1D9-AC9EB7E77F96Q38322277-1FA64095-B694-4C31-8E25-75C7D495E326Q39024745-82690EAF-9DEE-4AE0-A236-ACDB5B9D8731Q40338046-079AB609-0FC2-4EF4-B873-1EFA6B2F4C16Q40760824-7B7A9A9E-6C88-4BFA-A854-EA41C6DE690EQ41842699-10DDDD53-62CE-4FB4-8FF5-0897159C6866Q44310680-78817C2C-2D62-4EEC-8541-9BED2B06F171Q48784822-4CC33428-1F09-48EC-A2B1-F258BDD3C450Q54348577-26263EC1-E273-44FA-BA63-60CD3900681A
P2860
Mechanism of action and resistance to monoclonal antibody therapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Mechanism of action and resistance to monoclonal antibody therapy.
@ast
Mechanism of action and resistance to monoclonal antibody therapy.
@en
type
label
Mechanism of action and resistance to monoclonal antibody therapy.
@ast
Mechanism of action and resistance to monoclonal antibody therapy.
@en
prefLabel
Mechanism of action and resistance to monoclonal antibody therapy.
@ast
Mechanism of action and resistance to monoclonal antibody therapy.
@en
P1433
P1476
Mechanism of action and resistance to monoclonal antibody therapy.
@en
P2093
Emili Montserrat
Neus Villamor
P304
P356
10.1016/S0093-7754(03)00261-6
P577
2003-08-01T00:00:00Z